Allele Symbol Allele Name Allele ID |
Dll4tm2.1Vlcg targeted mutation 2.1, Velocigene MGI:5302387 |
||||||||||||||||||||
Summary |
4 genotypes
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• retinal capillaries from tamoxifen-treated mice are more resistant to oxygen-induced vaso-obliteration compared with control capillaries
|
• tamoxifen-treated mice exhibit reduced capillary regression during normal developmental capillary remodeling compared with control mice
|
• retinal capillaries from tamoxifen-treated mice are more resistant to oxygen-induced vaso-obliteration compared with control capillaries
|
• tamoxifen-treated mice exhibit reduced capillary regression during normal developmental capillary remodeling compared with control mice
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• severe as in Dll4tm1Nwg heterozygotes
|
• authors state that mice phenocopy Dll4tm1Nwg heterozygotes
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• abrogated maturation in mice treated with tamoxifen at P5
|
• abrogated maturation in mice treated with tamoxifen at P5
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 12/10/2024 MGI 6.24 |
|
|